Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
J Cancer Res Clin Oncol ; 147(6): 1763-1771, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33219855

ABSTRACT

PURPOSE: Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance remain unclear as they are situated in an interdisciplinary setting. METHODS: A questionnaire addressing the patterns of care and surveillance in the management of patients with uveal melanoma was distributed to 70 skin cancer centers in Austria, Germany and Switzerland. Frequency distributions of responses for each item of the questionnaire were calculated. RESULTS: 44 of 70 (62.9%) skin cancer centers completed the questionnaire. Thirty-nine hospitals were located in Germany (88.6%), three in Switzerland (6.8%) and two in Austria (4.5%). The majority (68.2%) represented university hospitals. Most patients with metastatic disease were treated in certified skin cancer centers (70.7%, 29/41). Besides, the majority of patients with UM were referred to the respective skin cancer center by ophthalmologists (87.2%, 34/39). Treatment and organization of follow-up of patients varied across the different centers. 35.1% (14/37) of the centers stated to not perform any screening measures. CONCLUSION: Treatment patterns of patients with uveal melanoma in Germany, Austria and Switzerland remain extremely heterogeneous. A guideline for the treatment and surveillance is urgently needed.


Subject(s)
Aftercare , Melanoma/therapy , Monitoring, Physiologic , Practice Patterns, Physicians'/statistics & numerical data , Uveal Neoplasms/therapy , Aftercare/methods , Aftercare/statistics & numerical data , Austria/epidemiology , Cross-Sectional Studies , Follow-Up Studies , Germany/epidemiology , Health Services Needs and Demand/statistics & numerical data , Humans , Mass Screening/methods , Mass Screening/statistics & numerical data , Melanoma/epidemiology , Melanoma/pathology , Monitoring, Physiologic/methods , Monitoring, Physiologic/statistics & numerical data , Neoplasm Metastasis , Neoplasm Recurrence, Local/epidemiology , Population Surveillance/methods , Referral and Consultation/standards , Referral and Consultation/statistics & numerical data , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Surveys and Questionnaires , Switzerland/epidemiology , Uveal Neoplasms/epidemiology , Uveal Neoplasms/pathology
2.
J Oncol Pharm Pract ; 26(7): 1774-1779, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32164491

ABSTRACT

INTRODUCTION: Immune checkpoint inhibitors are becoming increasingly important in oncology. Immune-related adverse events, including autoimmune hypophysitis, have been reported before. CASE REPORT: We present a case series of three males and one female, suffering from either malignant melanoma or renal cell carcinoma, who developed hypophysitis under Nivolumab and/or Ipilimumab. A wide range of clinical manifestations from asymptomatic hypophysitis, headache, general weakness, loss of appetite, visual field impairment, and confusion to acute life-threatening Addison crisis was observed.Management and outcome: All patients received corticosteroids. Immune checkpoint inhibitors were discontinued in three cases until resolution of symptoms. DISCUSSION: The objective of our report is to raise the awareness of physicians, regarding this rare clinical entity, which may become life-threatening, if not promptly recognized and properly treated.


Subject(s)
Autoimmune Hypophysitis/chemically induced , Immune Checkpoint Inhibitors/adverse effects , Ipilimumab/adverse effects , Nivolumab/adverse effects , Aged , Carcinoma, Renal Cell/drug therapy , Female , Humans , Immune Checkpoint Inhibitors/administration & dosage , Kidney Neoplasms/drug therapy , Male , Melanoma/drug therapy , Middle Aged
3.
J Mol Diagn ; 18(1): 75-83, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26607775

ABSTRACT

In melanoma, the mitogen-activated protein (MAP) kinase pathway plays a crucial oncogenic role. Recent studies identified additional genetic alterations, eg, TERT-promoter mutations. Up to 8% of melanoma patients present with multiple primary melanomas (MPMs). The pathogenesis is not fully understood, and data on the genetic diversity of MPMs are limited. To identify putative diagnostic and therapeutic consequences, we assessed the mutational status of the BRAF and NRAS genes and TERT promoter in patients with MPMs. The study cohort consisted of 96 patients with 237 malignant melanomas. The BRAF, NRAS, and TERT-promoter genotypes were assessed in all MPMs and were correlated with patients' clinicopathological characteristics. BRAF mutations were found in 84 melanomas (35.4%), NRAS mutations, in 33 (14.0%); and TERT-promoter mutations, in 112 (47.3%). Mutation patterns were concordant between first and subsequent primary tumors in 23.9% of patients and were discordant in 61.4% of patients. The genetic alterations were partially different in 14.7% of patients. By Cox regression analysis, only the NRAS mutation had a significant negative prognostic impact on time to progression to stage III (P = 0.016) and on distant metastasis-free survival (P = 0.032). In the majority of primary melanomas in patients with MPMs, BRAF, NRAS, and TERT-promoter genotypes were discordant. Thus, molecular testing for targeted therapy should be performed on metastatic tissue and not on primary tumors.


Subject(s)
GTP Phosphohydrolases/genetics , Melanoma/genetics , Membrane Proteins/genetics , Neoplasms, Multiple Primary/genetics , Promoter Regions, Genetic/genetics , Proto-Oncogene Proteins B-raf/genetics , Telomerase/genetics , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Genetic Variation/genetics , Genotype , Humans , MAP Kinase Signaling System/genetics , Male , Middle Aged , Molecular Diagnostic Techniques/methods , Mutation/genetics , Prognosis , Retrospective Studies , Surveys and Questionnaires
4.
J Transl Med ; 13: 351, 2015 Nov 06.
Article in English | MEDLINE | ID: mdl-26541511

ABSTRACT

BACKGROUND: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advanced melanoma seen in daily clinical practice, the Dermatologic Cooperative Oncology Group conducted a phase II study to assess the efficacy and safety of ipilimumab in patients with different subtypes of metastatic melanoma. PATIENTS AND METHODS: We undertook a multicenter phase II study in melanoma patients irrespective of location of the primary melanoma. Here we present data on patients with pretreated metastatic cutaneous, mucosal and occult melanoma who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. RESULTS: 103 pretreated patients received at least one dose of ipilimumab, including 83 cutaneous, seven mucosal and 13 occult melanomas. 1-year OS rates for cutaneous, mucosal and occult melanoma were 38 %, 14 % and 27 %, respectively. Median OS was 6.8 months (95 % CI 5.3-9.9) for cutaneous, 9.6 months (95 % CI 1.6-11.1) for mucosal, and 9.9 months (lower 95 % CI 2.3, upper 95 % CI non-existent) for occult melanoma. Overall response rates for cutaneous, mucosal and occult melanoma were 16 %, 17 % and 11 %, respectively. Eleven patients had partial response (16 %) and ten patients experienced stable disease (14 %), none achieved a complete response. Treatment-related AEs were observed in 71 patients (69 %), including 20 grade 3-4 events (19 %). No new and unexpected safety findings were noted. CONCLUSIONS: Ipilimumab is a treatment option for pretreated patients with advanced cutaneous melanoma seen in daily routine. Toxicity was manageable when treated as per protocol-specific guidelines. TRIAL REGISTRATION: Clinical Trials.gov NCT01355120.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Female , Humans , Ipilimumab , Kaplan-Meier Estimate , Male , Melanoma/mortality , Middle Aged , Remission Induction , Skin Neoplasms/mortality , Treatment Outcome , Melanoma, Cutaneous Malignant
5.
PLoS One ; 10(3): e0118564, 2015.
Article in English | MEDLINE | ID: mdl-25761109

ABSTRACT

PURPOSE: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to assess the efficacy and safety of ipilimumab in patients with metastatic UM. PATIENTS AND METHODS: We undertook a multicenter phase II study in patients with different subtypes of metastatic melanoma. Here we present data on patients with metastatic UM (pretreated and treatment-naïve) who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. RESULTS: Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab. 1-year and 2-year OS rates were 22% and 7%, respectively. Median OS was 6.8 months (95% CI 3.7-8.1), median progression-free survival 2.8 months (95% CI 2.5-2.9). The disease control rate at weeks 12 and 24 was 47% and 21%, respectively. Sixteen patients had stable disease (47%), none experienced partial or complete response. Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3-4 events (36%). One drug-related death due to pancytopenia was observed. CONCLUSIONS: Ipilimumab has very limited clinical activity in patients with metastatic UM. Toxicity was manageable when treated as per protocol-specific guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT01355120.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Melanoma/drug therapy , Uveal Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Female , History, Ancient , Humans , Ipilimumab , Kaplan-Meier Estimate , Melanoma/mortality , Melanoma/secondary , Middle Aged , Proportional Hazards Models , Treatment Outcome , Uveal Neoplasms/mortality , Uveal Neoplasms/pathology
6.
J Dtsch Dermatol Ges ; 13(9): 942-51, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26882393

ABSTRACT

When using procedures that enable complete examination of surgical margins (3D histology), microscopically controlled surgery (MCS) represents a safe and proven method to confirm R0 resection of infiltrating tumors, especially at problematic sites, while preserving the adjacent tissue. This allows for excellent or good aesthetic results that are superior (cryosurgery, short-range irradiation) or equivalent (PDT) to nonsurgical and less safe procedures (PDT).


Subject(s)
Dermatologic Surgical Procedures/standards , Microsurgery/standards , Neoplasms/pathology , Neoplasms/surgery , Practice Guidelines as Topic , Surgery, Computer-Assisted/standards , Dermatology/standards , Germany , Humans
7.
J Dtsch Dermatol Ges ; 12(7): 594-604, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24846553

ABSTRACT

BACKGROUND: In the context of DRG-based hospital funding, the analysis of services provided in dermatologic inpatient care is highly relevant. We analyzed and compared clinical service structures and varieties in dermatologic hospitals through a benchmarking technique. METHODS: For this multicenter cross-sectional study, routine data from 46 German dermatologic clinics and departments were collected, processed, and analyzed. In total, 95 257 data sets from 2011 were available. The data were grouped according to the G-DRG-system 2013 version. RESULTS: The average length of stay for all cases was 6.3 days (DRG "inliers": 5.7 days), and average patient age was 52 years. In total, 55 % of all cases were grouped to medical, 45 % to surgical DRGs. 71 % of all hospitals provide services within or close to this average value (± 10 %). No association was found between the number of hospital beds and the variety of clinical services provided in our sample. We found huge varieties in several parameters assessing the coding quality. CONCLUSIONS: The results reflect the heterogeneous reality in German inpatient dermatology. The varieties in dermatologic service range still depend on patient-related factors as well as infrastructural conditions and the resources available at each site.


Subject(s)
Dermatology/statistics & numerical data , Diagnosis-Related Groups/statistics & numerical data , Hospital Bed Capacity/statistics & numerical data , Length of Stay/statistics & numerical data , Skin Diseases/classification , Benchmarking , Dermatology/economics , Dermatology/standards , Diagnosis-Related Groups/economics , Diagnosis-Related Groups/standards , Female , Germany/epidemiology , Hospital Bed Capacity/economics , Hospital Bed Capacity/standards , Humans , Length of Stay/economics , Male , Middle Aged , Skin Diseases/diagnosis , Skin Diseases/economics , Skin Diseases/therapy
10.
Eur J Cancer ; 47(13): 1977-89, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21612915

ABSTRACT

AIM OF THE STUDY: To describe the current management of patients diagnosed with cutaneous melanoma and melanoma in situ in Germany and assess for adherence with the existing German guideline in a first prospective population-based analysis. METHODS: Prospective and longitudinal population-based study using online questionnaires. Registration by practitioners and hospitals was open for all patients diagnosed with melanoma between April and June 2008 in Germany. For data analysis, patients with melanoma stages 0-III (AJCC 2002) were included. RESULTS: Data from 1081 patients registered by 106 different centres were available for analysis. Male patients were significantly older than female patients (61.4 years versus 55.8years, p<0.0001) and presented with thicker primary tumours (1.62 mm [median 0.9 mm] versus 1.48 mm [median 0.8 mm], p=0.01). Excessive safety margin excisions were most often applied in melanoma in situ and in small centres. Insufficient excision margins (6.9%) were associated with head and neck localisation, geographical region and implementation of further staging procedures. Decision on sentinel lymph node biopsy complied with the German guideline in >85% of cases and was dependent on age and tumour localisation. Only 60% of patients received a complete lymph node dissection (CLND) after a positive SLNB, the rate of CLND was lowest in older patients. Adjuvant treatments were initiated in only 34% of patients formally qualifying for adjuvant treatment based on guideline recommendations. Approximately half of all staging procedures were done in no-risk/low-risk tumour patients. CONCLUSIONS: Management of melanoma in Germany did not show great dependency on centre size, geographical area or treating physician but rather on patient and tumour characteristics. The low rate of adjuvant treatment initiations reflects the need of treatment options in this patient group. Excessive initial staging procedures generate significant costs.


Subject(s)
Melanoma/diagnosis , Melanoma/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Germany , Guideline Adherence , Humans , Longitudinal Studies , Male , Melanoma/pathology , Middle Aged , Practice Patterns, Physicians' , Prospective Studies , Skin Neoplasms/pathology , Treatment Outcome , Young Adult
11.
J Dtsch Dermatol Ges ; 8(11): 920-5, 2010 Nov.
Article in English, German | MEDLINE | ID: mdl-20337775

ABSTRACT

To confirm a local R0 resection of tumors with infiltrative growth at problem sites and for sparing of tissue, microscopically controlled surgery represents a safe and proven method, particularly when there are no gaps between the tissue taken at the incision margins.


Subject(s)
Microscopy/standards , Mohs Surgery/standards , Robotics/standards , Skin Diseases/pathology , Skin Diseases/surgery , Surgery, Computer-Assisted/standards , Feedback , Humans
12.
J Dtsch Dermatol Ges ; 7(4): 318-27, 2009 Apr.
Article in English, German | MEDLINE | ID: mdl-19500194

ABSTRACT

The update of the G-DRG system for the year 2009 has been successfully negotiated. Like in the past years, changes are minimal and not dramatic, but they significantly enhance the quality of the DRG system. Once again, the German DRG system demonstrates its versatility and reliability for clinical reimbursement purposes. In the field of dermatology, several improvements or enhancements can be identified; the average case mix index that declined in the past years should now rise by 0.5 percent for 2009. Oncology cases are affected especially by this increase. Some refinements advanced for several years by the German Dermatologic Society (DDG) have been recognized --complex therapies like vacuum wound therapy, isolation due to multi-resistant infections and multiple primary tumors now have better cost weights. Although there still remain some minor problems like reimbursement of cost-intensive treatments, German dermatology is in summary very well prepared for the year 2009.


Subject(s)
Diagnosis-Related Groups/trends , Health Care Costs/standards , Health Care Costs/trends , Skin Diseases/classification , Skin Diseases/economics , Germany , Humans
13.
Melanoma Res ; 19(1): 8-16, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19430402

ABSTRACT

Several studies illustrated considerably elevated levels of cyclooxygenase-2 (COX-2) protein in various types of human cancer including malignant melanoma. Recently, it was reported that COX-2 is strongly expressed in malignant melanoma and may be correlated with the development and progression of disease. In contrast, other groups did not detect COX-2 protein in primary melanoma cells but did in infiltrating inflammatory cells or metastases. However, there are no reports about patterns or alterations of COX-2 expression in melanoma cells during disease progression or of a correlation between COX-2 expression and overall survival. The aim of this study was to investigate whether there is a correlation between expression of COX-2 protein and disease prognosis in malignant melanoma. We therefore analyzed the expression of COX-2 protein by immunohistochemistry in 101 primary malignant melanomas and 28 metastases and correlated our data with Breslow tumor thickness, Clark levels, different melanoma subtypes, metastases, and overall survival. We detected a strong COX-2 expression in 95% of all primary melanomas, primarily restricted to melanoma cells as shown by various immunohistochemical methods. Levels of COX-2 expression in primary melanoma and corresponding metastases remained stable. A significant correlation between immunohistochemical staining intensity and tumor thickness was demonstrated. Furthermore, Kaplan-Meier curves illustrated a significant correlation between staining intensity and disease-specific survival. Our findings emphasize that the COX-2 protein might be a novel prognostic marker. Owing to its strong expression in melanoma cells it might also be a reasonable therapeutic target.


Subject(s)
Biomarkers, Tumor/biosynthesis , Cyclooxygenase 2/biosynthesis , Melanoma/enzymology , Adult , Aged , Disease Progression , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Melanoma/pathology , Middle Aged , Neoplasm Invasiveness , Neoplasm Metastasis , Prognosis
14.
J Clin Oncol ; 27(21): 3496-502, 2009 Jul 20.
Article in English | MEDLINE | ID: mdl-19433681

ABSTRACT

PURPOSE Interferon alfa (IFN-alpha) has shown clinical efficacy in the adjuvant treatment of patients with high-risk melanoma in several clinical trials, but optimal dosing and duration of treatment are still under discussion. It has been argued that in high-dose IFN-alpha (HDI), the intravenous (IV) induction phase might be critical for the clinical benefit of the regimen. PATIENTS AND METHODS In an attempt to investigate the potential role of a modified high-dose induction phase, lymph node-negative patients with resected primary malignant melanoma of more than 1.5-mm tumor thickness were included in this prospective randomized multicenter Dermatologic Cooperative Oncology Group trial. Six hundred seventy-four patients were randomly assigned to receive 4 weeks of a modified HDI scheme. This schedule consisted of 5 times weekly 10 MU/m(2) IFN-alpha-2b IV for 2 weeks and 5 times weekly 10 MU/m(2) IFN-alpha-2b administered subcutaneously (SC) for another 2 weeks followed by 23 months of low-dose IFN-alpha-2b (LDI) 3 MU SC three times a week (arm A). LDI 3 MU three times a week was given for 24 months in arm B. Results Of 650 assessable patients, there were 92 relapses among the 321 patients receiving high-dose induction as compared with 95 relapses among the 329 patients receiving LDI only. Five-year relapse-free survival rates were 68.0% (arm A) and 67.1% (arm B), respectively. Likewise, melanoma-related fatalities were similar between both groups, resulting in 5-year overall survival rates of 80.2% (arm A) and 82.9% (arm B). CONCLUSION The addition of a 4-week modified HDI induction phase to a 2-year low-dose adjuvant IFN-alpha-2b treatment schedule did not improve the clinical outcome.


Subject(s)
Antineoplastic Agents/administration & dosage , Interferon-alpha/administration & dosage , Melanoma , Skin Neoplasms , Adult , Aged , Female , Humans , Infusions, Subcutaneous , Interferon alpha-2 , Longitudinal Studies , Male , Melanoma/drug therapy , Middle Aged , Prospective Studies , Recombinant Proteins , Skin Neoplasms/drug therapy , Young Adult
15.
J Dtsch Dermatol Ges ; 7(2): 135-8, 2009 Feb.
Article in English, German | MEDLINE | ID: mdl-19371235

ABSTRACT

Purpura fulminans features the sudden onset of large rapidly-spreading areas of hemorrhagic skin necrosis. This is followed by a disseminated intravascular coagulopathy with consecutive consumption of anticoagulant factors. Patients with severe disease in whom therapy is delayed often develop shock with a poor prognosis.The mortality rate is about 30-40%. An elderly women developed purpura fulminans after a respiratory infection. Prompt diagnosis before shock symptoms had started was instrumental in producing a favorable clinical course.


Subject(s)
Purpura Fulminans/diagnosis , Purpura Fulminans/etiology , Respiratory Tract Infections/complications , Respiratory Tract Infections/diagnosis , Aged , Female , Humans
16.
J Dtsch Dermatol Ges ; 7(8): 680-7, 2009 Aug.
Article in English, German | MEDLINE | ID: mdl-19250249

ABSTRACT

BACKGROUND: The G-DRG per case payments are calculated annually on the basis of present output and cost data provided from German hospitals. The economic valuation of dermatology-related DRGs depends largely on inpatients' length of stay. At present, longitudinal analyses of dermatologic hospital data considering the development of length of stay under DRG conditions are not available. METHODS: A multicenter, longitudinal study of clinical data from hospitals with different care levels was performed (n = 23). Frequent and relevant dermatologic diagnoses were grouped and analyzed over a time period of four years (2003-2006). The development of lengths of stay and of G-DRG cost weights were studied in detail. Descriptive statistical methods were applied. RESULTS: After introduction of DRG, the data reveal a) reduction of length of stay in inpatient dermatology and b) after an initial abrupt rise, DRG valuation of dermatologic groups moderately decreased over time. Both trends changed most rapidly in the early years but reached a stable niveau in 2006. The study furthermore points out that not only length of stay, but also other type of costs influence DRG calculations. CONCLUSIONS: German dermatology reflects the international trend showing reductions of length of stay after introduction of a DRG-based hospital funding system. The DRG calculation and valuation of inpatient services depend on the duration of hospital stay. However, increasing per diem costs resulting from higher performances of every inpatient bed day are also taken into account. Further reduction of length of stay must not threaten the quality of inpatient care in dermatology.


Subject(s)
Dermatology/economics , Diagnosis-Related Groups/economics , Health Care Costs/statistics & numerical data , Length of Stay/economics , Models, Economic , Dermatology/statistics & numerical data , Diagnosis-Related Groups/statistics & numerical data , Germany , Length of Stay/statistics & numerical data
17.
J Dtsch Dermatol Ges ; 7(5): 445-8, 2009 May.
Article in English, German | MEDLINE | ID: mdl-19178613

ABSTRACT

In Germany Fuchs syndrome is used to describe a variant of erythema multiforme majus which mainly involves the mucosal surfaces. As the skin may be completely unaffected, it is an under-recognized diagnosis and often difficult to confirm. Clinical features involve erythema, erosions and ulcerations of the oral mucosa. In most cases there is severe conjunctivitis and sometimes the genital mucosa is involved. Most cases of Fuchs syndrome are triggered by infections; herpes simplex virus and Mycoplasma pneumoniae are the most common causes. We describe two women presenting with Fuchs syndrome after respiratory illness caused by Mycoplasma pneumoniae.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Erythema Multiforme/diagnosis , Erythema Multiforme/drug therapy , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Mycoplasma/drug therapy , Adult , Erythema Multiforme/complications , Female , Humans , Pneumonia, Mycoplasma/complications , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...